GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » EV-to-FCF

Cambium Bio (ASX:CMB) EV-to-FCF : -13.47 (As of Mar. 04, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cambium Bio's Enterprise Value is A$2.13 Mil. Cambium Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.16 Mil. Therefore, Cambium Bio's EV-to-FCF for today is -13.47.

The historical rank and industry rank for Cambium Bio's EV-to-FCF or its related term are showing as below:

ASX:CMB' s EV-to-FCF Range Over the Past 10 Years
Min: -24.73   Med: -3.01   Max: 9.91
Current: -19.74

During the past 11 years, the highest EV-to-FCF of Cambium Bio was 9.91. The lowest was -24.73. And the median was -3.01.

ASX:CMB's EV-to-FCF is ranked worse than
100% of 419 companies
in the Biotechnology industry
Industry Median: 3.78 vs ASX:CMB: -19.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-04), Cambium Bio's stock price is A$0.30. Cambium Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.496. Therefore, Cambium Bio's PE Ratio (TTM) for today is At Loss.


Cambium Bio EV-to-FCF Historical Data

The historical data trend for Cambium Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio EV-to-FCF Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.91 8.15 -5.43 -5.74 -22.88

Cambium Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.43 - -5.74 - -22.88

Competitive Comparison of Cambium Bio's EV-to-FCF

For the Biotechnology subindustry, Cambium Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cambium Bio's EV-to-FCF falls into.



Cambium Bio EV-to-FCF Calculation

Cambium Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.129/-0.158
=-13.47

Cambium Bio's current Enterprise Value is A$2.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio  (ASX:CMB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cambium Bio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.30/-0.496
=At Loss

Cambium Bio's share price for today is A$0.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.496.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cambium Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cambium Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines